of the patient. The average daily dose of warfarin is 5 mg 1 ; however, some patients require doses much lower than this. Although a number of well-known external factors such as diet, concomitant medications, and physical activity may influence warfarin dosage requirements, their influence is sometimes unpredictable. There is a growing body of evidence that genetic variations in cytochrome P450 2C9 (CYP2C9), a key enzyme in warfarin metabolism, may provide a predictable, inherent explanation for reduced warfarin dosage requirements.
W arfarin is currently the only oral anticoagulant available in the United States for the prevention of thromboembolic events associated with disease states such as atrial fibrillation. It has a narrow therapeutic range and must be monitored frequently using the international normalized ratio (INR) in conjunction with the clinical presentation This study compared the frequency of variant cytochrome P450 2C9 (CYP2C9) alleles and warfarin S/R concentration ratio in patients who required lowdose (<2.5 mg/day) and average-dose (5 ± 0.5 mg/day) warfarin. Patients who achieved a therapeutic international normalized ratio were recruited from the Atlanta Veterans Affairs Medical Center anticoagulation clinic. CYP2C9*2 and *3 alleles were determined by validated Taqman allelic discrimination assays. Warfarin S and R concentrations were determined by chiral capillary electrochromatography with electrospray ionization mass spectrometry. At least 1 variant allele was found in 66.7% and 22.2% of patients in the low-dose and average-dose groups, respectively (P = .001, χ 2 ). The warfarin S/R concentration ratio was 0.665 (range, 0.162-3.58) and 0.452 (range, 0.159-2.36) for patients receiving low-dose and average-dose therapy, respectively (P = .097). A warfarin requirement of <2.5 mg/day and an elevated warfarin S/R concentration ratio were each associated with a higher frequency of variant CYP2C9 alleles.
Keywords: warfarin; cytochrome P-450 enzyme system; genetic polymorphisms; R-warfarin concentrations; S-warfarin concentrations metabolized by CYP3A4, CYP1A1, CYP1A2, and CYP2C19. 4, 5 CYP2C9 has been shown to exhibit genetic polymorphism resulting in reduced metabolism of substrate medications by carriers of variant alleles. Most CYP2C9 variants arise from amino acid substitutions in the coding region of the CYP2C9 gene. 4, 6 The metabolic activity of the variant alleles is often expressed as a percentage of the activity of CYP2C9*1, the wildtype allele. The most commonly reported variant alleles are CYP2C9*2 and CYP2C9*3. Compared with CYP2C9*1 homozygotes, the enzyme activity of CYP2C9*2 homozygotes is 80% to 84%, 7 whereas that of CYP2C9*3 is 20% but only 5% for S-warfarin, specifically. 8, 9 In addition, the variant alleles CYP2C9*4 through CYP2C9*12 have been identified more recently. [10] [11] [12] [13] CYP2C9*6 is a null variant with minimal activity that was originally identified in a black male patient. 13 In the absence of external factors, low warfarin dosage requirements may be explained by impaired warfarin metabolism. Two markers for identifying impaired metabolism would be relative concentrations of S-warfarin and R-warfarin and the CYP2C9 genotype. Reduced metabolism of the more potent S-warfarin would result in a higher concentration of S-warfarin relative to R-warfarin. CYP2C9 genotyping would reveal variant alleles that could, in turn, serve as the underlying reason for the impaired metabolism.
This study was designed to evaluate the association among warfarin dose requirements, frequency of variant CYP2C9 alleles, and relative concentrations of S-warfarin and R-warfarin. We conducted a prospective study at a Veterans Affairs Medical Center (VAMC) anticoagulation clinic. The primary objectives were to compare the frequency of variant CYP2C9 alleles in patients who required low-dose (<2.5 mg/day) and those who required average-dose (5 ± 0.5 mg/day) warfarin therapy and to determine the differences in warfarin S/R concentration ratio among patients with various CYP2C9 genotypes. Secondary objectives were to examine the effects of smoking and CYP1A2*1F genotypes on R-warfarin concentration.
Methods

Study Setting and Design
This study was approved by the Emory University Institutional Review Board, the Mercer University Institutional Review Board, the Atlanta VAMC Research and Development Committee, and the Georgia State University Institutional Review Board. All participants gave informed consent.
This study was conducted at the pharmacist-run Atlanta VAMC anticoagulation clinic. Approximately 1400 patients attend this clinic every year at intervals of up to 8 weeks. Once warfarin is initiated, patients are referred to this clinic by their primary care provider. Dosage adjustments are determined by INR results and clinical presentation. Frequency of follow-up is based on trends in an individual patient's laboratory results, clinical stability, and compliance history. Depending on patient acuity, dosage adjustments are evaluated within 3 weeks. Once the INR pattern and clinical presentation are both stable, routine follow-up is scheduled every 4 to 8 weeks.
Participants
Participants were recruited from among the population served at any outpatient clinic associated with the Atlanta VAMC. Inclusion criteria included a warfarin dose of less than 2.5 mg/day (17.5 mg/ week) or 5 ± 0.5 mg/day (35 ± 3.5 mg/week) and an INR within the therapeutic range for the condition being treated for at least 2 consecutive visits separated by at least 10 days. An INR range of 2.0 to 3.0 was used for most conditions, with a higher range of 2.5 to 3.5 used for certain types of heart valve replacements and some patients with a history of recurrent thromboembolic events. The 2 study groups were called the low-dose group and average-dose group, respectively.
Exclusion criteria included any of the following: concomitant therapy with medications having welldocumented interactions with warfarin, unstable or poorly controlled congestive heart failure, liver disease (cirrhosis, elevated liver enzymes), hepatic cancer, liver metastases, end-stage renal disease, dietary deficiency of vitamin K, or acute alcoholism.
Patients meeting dose requirements were identified by prospectively checking the current warfarin dose of established anticoagulation clinic patients with upcoming appointments, by retrospectively checking the current warfarin dose of new anticoagulation clinic patients with recent appointments, or by referral from clinic providers. Medical records of patients were then screened to verify whether the dose requirements were met and as a preliminary method of determining whether the other eligibility criteria were met. The study was then discussed with prospective participants in person at a regularly scheduled clinic appointment or by telephone before a scheduled appointment. Once patients agreed to consider participation, they were interviewed in person to determine whether they met all eligibility requirements.
Once eligibility was determined and consent obtained, a 5-mL blood sample was collected in ethylenediaminetetraacetic acid tubes at the VAMC laboratory. After centrifugation, the plasma and buffy coat were separated into 2 vials and frozen at −78°C. The plasma was used to determine the R-warfarin and S-warfarin concentrations, and the buffy coat was used for genotyping.
Genotyping
Genomic DNA was isolated from about 2 mL of buffy coat−enriched whole blood using the QIAamp Blood Mini Kit (Qiagen, Valencia, Calif) or the Gentra Systems Blood Kit (Minneapolis, Minn). Genotyping for CYP2C9 and CYP1A2 was performed using validated Taqman allelic discrimination assays (Applied Biosystems, Foster City, Calif). The listed part numbers for these assays are: CYP2C9*2 (4312559), CYP2C9*3 (4312560), and CYP1A2*1F (C_8881221_10). The primer sequences for CYP2C9*2/*3 and CYP1A2*1F were taken from Higashi et al 14 and Sachse et al, 15 respectively.
The sequences of the primers and probes for these assays were validated to ensure specificity and accuracy of each assay by separate polymerase chain reaction (PCR) assays and DNA sequencing reactions. Each assay was performed with appropriate positive and negative controls using DNA samples collected from the University of Washington liver bank, which has been genotyped. These control samples were used for the Taqman and sequencing assays. The assignment of genotype for all 3 single nucleotide polymorphisms tested was unambiguous in all subjects tested, with the exception of 2 samples. In both instances, DNA sequencing provided unequivocal allele identification. All genotype assays passed the quality test.
The presence of CYP2C9*6 allele was determined by PCR-restriction fragment length polymorphism in 1 black patient, as described previously. 13, 16 
Analysis for Enantiomeric Concentrations of Warfarin in Human Plasma
The concentrations of R-warfarin and S-warfarin in human plasma were determined by chiral capillary electrochromatography coupled to electrospray ionization mass spectrometry (CEC-ESI-MS), as described by Zheng et al 17 and Zheng and Shamsi. 18 All CEC-ESI-MS experiments were done with an Agilent capillary electrophoresis instrument interfaced to a single quadruple mass spectrometer, Agilent 1100 series MSD (Agilent Technologies, Palo Alto, Calif). The CEC-MS columns were packed with 75 μm of internally tapered capillaries (Polymicro Technologies, Phoenix, Ariz). The Agilent Chemstation and CE-MS add-on software were used for instrument control and data analysis.
All blank and participant plasma samples were stored at −78°C until analysis. For each blank plasma sample, a 100-μL aliquot of plasma was mixed with 100 μL of water and spiked with a racemic warfarin solution at levels of 0.2, 0.5, 1.0, 2.5, 5.0, and 10.0 μg/mL. An internal standard of racemic coumachlor was added at a fixed concentration of 2.0 μg/mL in each of the 6 microcentrifuge tubes. The content of each tube was acidified with 0.2 mL of 10% perchloric acid, vortexed for 30 seconds, and centrifuged at 10 000 rpm for 10 minutes.
The supernatant of each tube was then transferred to a mixed-mode anion solid-phase extraction column (Waters, Milford, Mass), which was conditioned with 2 mL of 2% ammonium hydroxide and 2 mL of water before elution of racemic warfarin and racemic coumachlor with 2 mL of 50:50:5 acetonitrile/methanol/formic acid (v/v/v). The eluate from the solid-phase extraction column was evaporated to dryness in a water bath at 60°C in nitrogen. The inner wall of each tube was rinsed twice with 100 μL of methanol, followed by evaporation to obtain a dry residue.
Finally, this residue was reconstituted with 50 μL of 40% (v/v) acetonitrile and injected into the CEC-MS column. The sample preparation procedure for patient plasma was the same as the spiked blank human plasma, except no racemic warfarin was spiked. The experimental limit of detection was approximately 25 ng/mL for both enantiomers of warfarin.
Statistical Analysis
Normality of parameter distribution was assessed by the Shapiro-Wilk W test before any subsequent analyses. The differences in the proportion of patients with 1, 2, or 1 or 2 CYP2C9 variant alleles between the average-dose and low-dose groups were analyzed by χ 2 or Fisher exact test, as appropriate. The differences in age, S-warfarin and R-warfarin concentrations, and warfarin S/R concentration ratio between 2 or among multiple groups were determined by Wilcoxon rank sum test or Kruskal-Wallis analysis of variance, as appropriate. Probabilities for post hoc comparisons of the average ranks for each pair of groups were corrected for the number of comparisons. Statistical significance was set at a value of P ≤ .05, and all analyses were performed using Statistica 6.1 software (StatSoft, Tulsa, Okla).
Results
The preliminary dosage information and referrals from clinic providers were used to review 129 medical records, and 80 patients were initially determined to be eligible. Of these, 49 were excluded because of medication interactions (n = 28), not meeting dosage requirements upon verification (n = 11), malignancy (n = 8), and acute alcoholism (n = 2). As part of a pilot study, 2 patients were recruited between November 2000 and February 2001. Once funding for a larger study was obtained, 52 patients were recruited between February 2003 and November 2004. Table 1 summarizes the demographic characteristics of the participants, of which 94.4% were men, 75.9% were white, and 24.1% were black. The mean age of all participants was 70.7 years, and there was no significant age difference between the 2 groups. The mean weekly warfarin dose in the average-dose group was 35 ± 1.55 mg and that in the low-dose group was 13.1 ± 2.44 mg. Table 2 summarizes the distribution of CYP2C9 genotypes within the cohort. Of the participants taking an average dose, 77.8% were homozygous for the wild-type allele (CYP2C9 *1/*1), and 22.2% had 1 variant CYP2C9 allele. Of the participants taking a low dose, 33.3% were homozygous for the wild-type allele (CYP2C9 *1/*1), 55.5% had 1 variant CYP2C9 allele, and 11.1% had 2 variant CYP2C9 alleles. The presence of more than 1 variant CYP2C9 allele was observed only in participants in the low-dose group. Of the white participants, 48.8% were homozygous for the wild-type allele, 46.4% had 1 variant allele, and 4.8% had 2 variant CYP2C9 alleles. Of the black participants, 76.9% were homozygous for the wild-type allele, 15.4% had 1 variant allele, and 7.7% had 2 variant CYP2C9 alleles. Table 3 summarizes the number and percentage of participants with varying numbers of CYP2C9 variant alleles. The number of participants in the low-dose group having 1 variant allele was 55.6%, but only 22.2% of those in the average-dose group had 1 variant allele (P = .012). No participants taking an average dose of warfarin were found to have 2 variant alleles, whereas 11.1% of those taking a low dose had 2 variant alleles (P = .118). The number of participants in the low-dose group having 1or 2 variant alleles was 66.7%, whereas only 22.2% of those in the average-dose group had 1 or 2 variant alleles (P = .001). Table 4 summarizes the odds ratios of having variant CYP2C9 allele(s) stratified by warfarin dose. Within the average-dose group, 33.3% of white subjects had at least 1 variant allele, but no black subjects had variant alleles. Within the low-dose group, 65.2% of white subjects had at least 1 variant allele, and 75% of black subjects had variant alleles. The odds ratio for participants receiving a low dose of warfarin having at least 1 variant CYP2C9 allele compared with participants receiving an average dose of warfarin was 7 (range, 2.09-23.5). In patients identified as white, the odds ratio for participants receiving a low dose of warfarin having at least 1 variant CYP2C9 allele compared with participants on an average dose of warfarin was 3.75 (range, 1.02-13.8). This odds ratio was not determined for patients identified as black owing to the absence of patients carrying variant alleles in the average-dose group. Table 5 compares the S-warfarin and R-warfarin concentrations, and the S/R concentration ratio between the average-dose and low-dose groups. The median S-warfarin concentration was 0.651 μg/mL in the average-dose group and 0.352 μg/mL in the low-dose group (P < .01). The median R-warfarin concentration was 1.30 μg/mL in the average-dose group and 0.661 μg/mL in the low-dose group (P < .001). The warfarin S/R ratio was 0.452 in the average-dose group and 0.665 in the low-dose group (P = .097). Table 6 summarizes the S-warfarin and R-warfarin concentrations and the S/R concentration ratio for participants with varying numbers of variant CYP2C9 alleles. The average S-warfarin concentration was 0.505 μg/mL in participants with no variant CYP2C9 alleles and 0.456 μg/mL in those with at least 1 variant allele (P = .862). The average R-warfarin concentration was 1.16 μg/mL in participants with no variant CYP2C9 alleles and 0.689 μg/mL in those with at least 1 variant allele (P < .002). The warfarin S/R ratio was 0.446 in participants with no variant alleles and was 0.713 in those with at least 1 variant allele (P = .002). Figures 1 and 2 illustrate the differences in R-warfarin concentration and warfarin S/R concentration ratio among subjects with various CYP2C9 genotypes, respectively. R-warfarin concentration was significantly different among subjects with various CYP2C9 genotypes. Post hoc comparisons showed that the median R-warfarin concentration of 0.483 μg/mL for CYP2C9*1/*3 participants was significantly lower than the median R-warfarin concentration of 1.16 μg/mL for CYP2C9*1/*1 participants (P = .001). Significant differences in warfarin S/R ratio were observed among participants with various CYP2C9 genotypes. The median warfarin S/R ratio was highest in CYP2C9*1/*3 participants (0.737 [range, 0.256-2.070]), followed by CYP2C9*1/*2 (0.632 [range, 0.194-2.36]), and CYP2C9*1/*1 participants (0.446 [range, 0.159-0.882]).
The CYP1A2 genotype was determined in all except for 2 subjects: 26 were CYP1A2*1F/*1F, 23 were CYP1A2*1A/*1F, and 3 were CYP1A2*1A/ *1A. Five participants were smokers, and they were all CYP2C9 heterozygotes, of which 3 and 1 were heterozygous and homozygous for the CYP1A2*1F allele, respectively, and the CYP1A2 genotype was not determined for the other subject. Because of the small number of smokers, the effect of CYP1A2 genotype on warfarin concentrations in smokers could not be determined. There was a trend towards a lower R-warfarin concentration in CYP2C9 heterozygotes who were smokers than in those who were nonsmokers: median R-warfarin concentrations were 0.404 ng/mL (range, 0.293 to 0.627 ng/mL) in 4 smokers and 0.707 ng/mL (range, 0.195-2.42 ng/mL; P = .073) in 17 nonsmokers.
Discussion
Several studies have evaluated the relationship between CYP2C9 polymorphisms and warfarin dose, 19, 20 warfarin clearance, 20, 21 and clinical indicators of warfarin efficacy and toxicity. 14, 19 They have shown that patients with variant CYP2C9 alleles have a reduced dosage requirement for warfarin, [19] [20] [21] reduced clearance of S-warfarin, 20, 21 and an increased risk of elevated INRs, 14 bleeding complications, 14, 19 and difficulties during warfarin initiation. 14, 19 Our study showed a profound difference between the low-dose and average-dose groups in the presence of variant CYP2C9 alleles. In the lowdose group (<17.5 mg/week), 66.7% of participants had at least one variant CYP2C9 allele compared with only 22.2% in the average-dose group (31.5-38.5 mg/week; refer to Tables 2, 3, and 4). These results are similar to those of Scordo et al, 20 in which the percentage of participants with at least 1 variant allele was 70.3% in the low-dose group (<26.25 mg/week), 37.5% in the medium-dose group (26.25-43 .75 mg/week), and 4.2% in the high-dose group (>43.75 mg/week). The small differences in results may be due to differences in the dosage criteria for the groups. Compared with Scordo et al, 20 we used a narrower dosage range for both the lowdose and average-dose groups. From a different perspective, these data show that patients receiving a low dose had an odds ratio of 7 for having at least 1 variant CYP2C9 allele compared with those receiving an average dose, which is consistent with results from Aithal et al, 19 in which the calculated odds ratio was 6.62 (refer to Table 4 ).
The slight difference between groups in the average age of participants warrants some consideration. The participants in the low-dose group were a mean 4 years older than those in the average-dose group (refer to Table 1 ). Previous studies have shown that warfarin dose requirements decrease an average of 0.6 mg for every decade of life between 55 and 85 years irrespective of CYP2C9 polymorphism. 22, 23 However, the small age difference in the current study was unlikely responsible for the large difference in warfarin dose requirements.
As expected, the warfarin S/R ratio was significantly higher in patients with at least 1 variant allele compared with those with no variant alleles (P = .002). Of interest was that this increased ratio was not related to an increase in the S-warfarin concentration but was associated with a decrease in the R-warfarin concentration. In this study, the concentration of S-warfarin was comparable between patients with at least 1 variant CYP2C9 allele and those with no variant alleles, but the concentration of R-warfarin was significantly lower in patients with at least 1 variant allele (P < .002; refer to Table 6 ). Of note, R-warfarin is metabolized by multiple CYP enzymes. 4, 5 Its concentration value is probably related to its overall metabolism by these enzymes and, therefore, may not directly reflect the metabolic activity of CYP2C9, alone. On the contrary, our results for the warfarin S/R ratio were in agreement with previous findings, 20 suggesting that the S/R ratio is a better phenotypic biomarker for altered warfarin metabolism and CYP2C9 activity.
Previously, Scordo et al 20 found that the warfarin S/R ratio was higher in participants with 2 variant alleles and varied according to the following order: *3/*3 > *3/*2 > *2/*2 > *3/*1 > *2/*1 > *1/*1. Our results were similar to those of Scordo et al, 20 showing a difference in warfarin S/R ratio and a similar genotype rank for S/R ratio (ie, *1/*3 > *1/*2 > *1/*1) among patients with various CYP2C9 genotypes (refer to Figure 2 ). Furthermore, the warfarin S/R ratio was significantly higher in *1/*3 than in *1/*1 but not *1/*2 than in *1/*1, indicating that patients with *1/*3 have a lower CYP2C9 activity than those with *1/*2. These results are consistent with the observation that the *3 allele is associated with a larger reduction in metabolic CYP2C9 activity compared with the *2 allele. [6] [7] [8] [9] One limitation of the current study is that genotyping analysis was not performed in our black cohort for CYP2C9*5 and CYP2C9*6, which have been found predominantly in populations of African ancestry 10, 24, 25 and have been associated with decreased metabolism of warfarin, 10 phenytoin, 13, 26 and lorsartan. 27 Genotype results for 1 CYP2C9*6 homozygote from a previous case report were included, however. 16 Nevertheless, complete concordance between CYP2C9 genotype and warfarin dosage was found in black but not white participants in the average-dose group (Table 4) , and CYP2C9 variants accounted for reduced warfarin dosage in 75% of black but only 65.2% of white patients in the lowdose group. These results suggest that CYP2C9 polymorphism may be the major attributing factor for reduced warfarin dosage requirements in black compared with white patients. Notably, other factors such as age, body surface area, target INR, concurrent medications, and vitamin K epoxide reductase complex subunit 1 (VKORC1) genetic polymorphisms may also influence warfarin dose. 23, 24, 28, 29 In a subgroup analysis of patients with CYP2C9*1/*1, we found that the warfarin S/R ratio appeared to be higher in blacks (n = 10) compared with whites (n = 20) at 0.555 (range, 0.200-0.882) versus 0.391 (range, 0.159-0.765; P = .082), suggesting a lower warfarin clearance in blacks. These results are contrary to those of Takahashi et al 30 showing a higher unbound oral clearance in Japanese than in white patients and indicate that currently known CYP2C9 coding region polymorphisms cannot fully account for the differences in CYP2C9 activity. As previously discussed, our current observation may be associated with additional genetic variations, as well as environmental, dietary, and other unidentified factors. Because of the small sample size in our study, the ethnic differences in CYP2C9 activity between whites and blacks remain to be confirmed.
Our results showed that median R-warfarin concentration tended to be lower in CYP2C9 heterozygote subjects who were smokers than those who were nonsmokers. This finding is not unexpected, because cigarette smoking is known to induce CYP1A2 activity and R-warfarin is partially metabolized by CYP1A2. Previously, genetic polymorphisms in CYP1A2 have been shown to affect CYP1A2 inducibility in smokers. Although CYP1A2 activity (as determined by caffeine metabolite ratio) was decreased in subjects who carried the CYP1A2*1C allele, 31 enzyme activity was increased in homozygous CYP1A2*1F variants. 15 Hypothetically, R-warfarin would be higher and lower in smokers who carry the CYP1A2*1C and CYP1A2*1F allele, respectively; however, only 5 smokers were found in our study. Thus, a comparison of R-warfarin between subjects with different CYP1A2*1F genotypes could not be made.
Conclusion
Our study showed that a warfarin requirement of less than 2.5 mg/day was strongly associated with a higher frequency of CYP2C9 variant alleles and that an elevated warfarin S/R concentration ratio was associated with CYP2C9 variants. Further studies are needed to elucidate whether there are individual differences in CYP2C9 activity.
